查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球细胞表面标记物检测市场 - 2023-2030
市场调查报告书
商品编码
1279707

全球细胞表面标记物检测市场 - 2023-2030

Global Cell Surface Markers Detection Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球细胞表面标记物检测市场规模预计将在 2022 年达到 49.765 亿美元，并在 2030 年达到 95.226 亿美元，增长势头强劲。 在预测期内（2023-2030 年），该市场的复合年增长率将达到 8.7%。

细胞表面标记检测用于通过流式细胞术使用特定抗体结合的特定膜蛋白（即表面标记）来分离荧光细胞。 用于通过荧光激活细胞分选 (FACS) 分析识别和纯化人类造血干细胞的细胞表面标记检测包含许多分化簇 (CD) 标记。 最原始的人类造血干细胞已被鑑定为 CD34+CD90+，其他细胞群为 CD34+CD38。

即使在没有CD45RA表达的情况下，它也可以与上述标记物结合使用来鑑定原始造血干细胞。 人多能祖细胞被鑑定为 LinCD34+CD38CD90c-kitloflt3loCD133+CD45RA。 CMP（红细胞、粒细胞、巨核细胞、巨噬细胞）和 CLP（B 细胞、T 细胞、NK 细胞）的分化后代在 FACS 分析中通过谱系特异性标记物的存在来区分。 如B淋巴细胞为CD45+CD20+CD24+，T淋巴细胞为CD45+CD3+，巨核细胞为CD42b+，粒细胞为CD45+CD15+CD24+CD114+CD182+，巨噬细胞为CD45+CD68+。

市场动态

诊断的兴起、对精准医学的需求和技术进步推动了市场增长

精准医学是一个旨在根据特定患者群体的分子和环境因素提供医疗服务的概念。 生物标誌物辅助治疗是精准医学的一个重要分支学科，包括促进突变、蛋白表达、mRNA、MSI（微卫星不稳定性）、肿瘤突变负荷（TMB）、表观遗传生物标誌物等的增加。 生物标誌物基于 DNA、mRNA 和蛋白质，包括易化子突变、蛋白质表达、mRNA、MSI、肿瘤突变负荷 (TMB) 和表观遗传生物标誌物。

流式细胞术、免疫组织化学 (IHC) 和新一代测序（RNA 测序）是用于鑑定或诊断人群中细胞表面标誌物检测的方法。 RNA-Seq 使用新一代测序技术对 cDNA 进行并行测序，产生大量描述 RNA 片段中碱基对序列的数据。 用于细胞表面标记物检测的更多和更快的诊断正在推动市场。

设备成本高

流式细胞术等昂贵的设备及其复杂性是阻碍市场增长的主要原因。 流式细胞术的成本因地区而异，但非常昂贵。 例如，有索尼等厂家已经开始做10万日元以下的流式细胞仪设备，但一台10万到50万日元之间仍有可能。 因此，这是抑制细胞表面标记检测市场增长的主要因素。

COVID-19 影响分析

COVID-19 大流行预计将对市场产生重大影响，因为细胞表面标记物检测附着在细胞膜上，并在细胞间信号传导中发挥重要作用。 考虑 COVID-19 抗体与细胞表面标记检测相互作用的研究项目正在进行中，包括比较 COVID-19 患者和健康对照单核细胞中的细胞表面标记检测。

这项研究发现 COVID-19 患者的真菌合併感染率很高，这导致创新方法可以更好地了解该疾病并找到治疗方法。 此外，细胞表面标记检测已被用于研究 COVID-19 在大流行期间的影响。

俄乌衝突分析

俄乌衝突正在全球范围内产生负面影响，尤其是在东欧、欧盟、东/中亚和美国。 对乌克兰的负面影响，预计对俄罗斯的长期影响。 战争会影响供需平衡、价格波动、进出口、贸易，并对细胞表面标记物检测市场产生短期影响。

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按产品分类的片段
  • 片段：按应用
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 诊断的增加、对精准医学的需求、技术进步
    • 约束因素
      • 设备成本增加
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法律法规分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • COVID-19 期间的情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章副产品

  • 流式细胞仪
  • 血液分析仪
  • 细胞成像系统
  • 试剂和试剂盒
  • 其他

第八章应用

  • 疾病诊断与鑑定
  • 研究和药物发现
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第11章公司简介

  • 商务部
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Nihon Kohden Corporation
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Nexcelom Bioscience LLC
  • Beckman Coulter Inc.
  • Qiagen NV
  • IVD Medical Holding Limited（Immucor Inc.）
  • Agilent Technologies Inc.
  • Luminex Corporation.

第12章 附录

简介目录
Product Code: MD3902

Market Overview

The global cell surface markers detection market size reached US$ 4,976.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,522.6 million by 2030. The market is exhibiting at a CAGR of 8.7% during the forecast period (2023-2030).

The cell surface marker is used to separate fluorescent cells by flow cytometry by using a specific membrane protein (i.e., surface marker) bound by a specific antibody. The cell surface markers used for the identification and purification of human HSCs by fluorescence-activated cell sorting (FACS) analysis incorporate a number of clusters of differentiation (CD) markers. The most primitive human HSC is identified as CD34+CD90+, while other groups have identified it as CD34+CD38.

Absent expression of CD45RA has also been used in combination with the above markers for the identification of primitive HSCs. Human multipotent progenitor cells are identified as LinCD34+CD38CD90c-kitloflt3loCD133+CD45RA. Differentiated progeny of CMP (erythrocytes, granulocytes, megakaryocytes, and macrophages) and CLP (B cell, T cell, NK cell) is identified by the presence of lineage-specific markers in FACS analysis. For Instance, B- lymphocytes are CD45+CD20+CD24+, T-lymphocytes are CD45+CD3+, megakaryocytes are CD42b+, granulocytes are CD45+CD15+CD24+CD114+CD182+, and macrophages are CD45+CD68+.

Market Dynamics

Increased Diagnostics, Demand For Precision Medicine, And Technological Advancements Drive The Market Growth

Precision medicine is a concept that aims to align medical care with the molecular and environmental factors of certain patient groups. Biomarker-supported therapy is an essential sub-discipline of precision medicine, which includes driver mutations, protein expression, mRNA, MSI (microsatellite instability), tumor mutational burden (TMB), and epigenetic biomarkers. Biomarkers are DNA-, mRNA-, or protein-based and include driver mutations, protein expression, mRNA, MSI, tumor mutational burden (TMB), and epigenetic biomarkers.

Flow Cytometry, Immunohistochemistry (IHC), and Next Generation Sequencing (RNA Sequencing) are methods used to identify or diagnose the cell surface markers in a population. RNA-Seq uses next-generation sequencing to sequence cDNA in parallel to create large amounts of data showing the sequence of base pairs found in RNA fragments. Increased and quick diagnostics for cell surface markers detection drives the market.

High Cost of the Instruments

Expensive instruments like flow cytometry and their complexity are the main reasons to hamper the market growth. The cost of the flow cytometry varies from region but it is very expensive. For instance, some manufacturers, such as Sony, are beginning to build flow cytometer instruments that cost under $100,000, but it's still possible to spend anywhere from $100,000 to $500,000 for a single unit. So, this is the main factor hindering the market growth of cell surface markers detection.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to have a significant impact on the market, as cell surface markers are attached to the cell membrane and play a crucial role in intercellular signaling. Research projects are being conducted that involve the interaction of COVID-19 antibodies with cell surface markers, such as comparing the cell surface marker expression on monocytes of COVID-19 patients with healthy controls.

This study found an increased rate of fungal co-infections in COVID-19 patients, leading to a better understanding of the disease and innovative ways to find a cure. The cell surface markers are also used to study the effect of COVID-19 during the pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine Conflict has caused negative impacts globally, particularly in Eastern Europe, the European Union, Eastern & Central Asia, and the United States. It is expected to have an adverse impact on Ukraine and long-term effects on Russia. Due to the wars, implications for demand-supply balances, pricing variants, import/export and trading, short-term impact can be seen in the cell surface markers detection market.

Segment Analysis

The global cell surface markers detection market is segmented by product and by application.

Flow Cytometry Segment is Expected to dominate the market growth

Flow cytometry is a technique used to detect the presence of cell types within a population by passing single cells through a highly focused laser. Antibodies specific to cell surface markers of interest are added to a sample and allowed to bind to the cells. These antibodies are conjugated to fluorochromes which emit light at various wavelengths. The population of cells is then passed through a laser, exciting the fluorochromes and capturing the light emitted.

The cells are then sorted into subpopulations based on the markers present through a series of histograms and dot plots called a gating strategy. Flow cytometry allows for multiple cell surface markers on a cell to be detected, but nonspecific binding and spectral overlap can become a limitation. Flow cytometry also does not allow for the spatial aspect of a sample to be analyzed as the cells are suspended and fed through the laser one at a time. The flow cytometry segment holds about 37.6% of the total cell surface markers market in the forecast period owing to its multiple advantages in analysing cell surface markers.

Geographical Analysis

The Strong Presence Of The Clinical Research Sector And Increased Awareness About Cell Surface Markers

The North America region holds the largest share of the global cell surface markers detection market accounting for approximately 39.7% in the forecast period owing to the strong presence of the clinical research sector in the region's developed economies. The presence of leading players in the medical research sector has elevated the medical research sector in North America and the strong presence of cellular researchers in North America is likely to be a major driver for the market. The increased awareness about the cell surface markers is more likely to drive the market in North America.

Competitive Landscape

The major global players in the market include: BD, Nihon Kohden Corporation, Sysmex Corporation, Thermo Fisher Scientific, Grifols, Bio Rad Laboratories Inc., Agilent Technologies Inc., Nexcelom Bioscience LLC, Beckman Coulter Inc., IVD Medical Holding Limited (Immucor Inc.), and Luminex Corporation.

Why Purchase the Report?

  • To visualize the global cell surface markers detection market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cell surface markers detection market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global Cell Surface Markers Detection Market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Diagnostics, Demand for Precision Medicine, and Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Instruments
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Flow Cytometry*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology Analyzers
  • 7.4. Cell Imaging Systems
  • 7.5. Reagents and Kits
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Disease Diagnosis And Identifications*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Research And Drug Discovery
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. BD*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Nihon Kohden Corporation
  • 11.3. Sysmex Corporation
  • 11.4. Thermo Fisher Scientific
  • 11.5. Nexcelom Bioscience LLC
  • 11.6. Beckman Coulter Inc.
  • 11.7. Qiagen NV
  • 11.8. IVD Medical Holding Limited (Immucor Inc.)
  • 11.9. Agilent Technologies Inc.
  • 11.10. Luminex Corporation.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us